Peptide Therapy
PT-141 (BREMELANOTIDE)
What it is, how it works, how it compares to Viagra and Cialis, dosing protocols, side effects, and how to get FDA-approved PT-141 through a medical provider.
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC · Updated March 24, 2026
Book Consultation
WHAT IS PT-141?
PT-141, also known as bremelanotide, is a synthetic peptide that increases sexual desire and arousal by acting on the melanocortin system in the central nervous system. In June 2019, the FDA approved PT-141 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is one of only a handful of peptides with full FDA approval.
PT-141 was originally discovered as a side effect during research on melanotan II, a synthetic tanning peptide. Researchers noticed that melanotan II consistently produced increased sexual arousal in study participants. PT-141 was developed as a more targeted derivative, isolating the sexual desire effects without the skin-darkening properties. This is one of the more interesting origin stories in pharmacology — a drug designed for one purpose revealing an entirely different mechanism.
What makes PT-141 fundamentally different from every other sexual dysfunction treatment on the market is where it works. Viagra, Cialis, and tadalafil are PDE5 inhibitors — they work on blood flow to the genitals. They address the mechanics of erection. PT-141 works in the brain. It activates melanocortin-4 receptors (MC4R) in the hypothalamus, increasing dopamine signaling in the brain's reward and desire pathways. It addresses the wanting, not just the plumbing.
This distinction matters clinically. A significant percentage of patients with sexual dysfunction don't have a blood flow problem — they have a desire problem. PDE5 inhibitors do nothing for that. PT-141 can work when Viagra and Cialis don't because it's targeting an entirely different part of the system.
Key distinction: PT-141 addresses sexual desire at the brain level. PDE5 inhibitors (Viagra, Cialis, tadalafil) address erection mechanics via blood flow. They solve different problems. Many patients benefit from both — they're complementary, not competing.
PT-141 BENEFITS
PT-141 is the only FDA-approved treatment that targets sexual desire through the central nervous system. Clinical trials demonstrated statistically significant increases in desire and arousal in both women and men.
Increased Sexual Desire
The primary effect. PT-141 activates the brain's desire pathways directly, producing genuine increases in wanting — not just the physical ability to perform. This is the effect that led to FDA approval. Clinical trials showed statistically significant improvements in desire scores compared to placebo.
Enhanced Arousal
Beyond desire, PT-141 increases physiological arousal through central nervous system activation. This includes both subjective arousal (feeling turned on) and measurable genital arousal responses. The effect is reported in both men and women.
Works for Both Men and Women
While the FDA approval is for premenopausal women with HSDD, the melanocortin receptor system is not sex-specific. Clinical studies have demonstrated efficacy in men, particularly those with erectile dysfunction who don't respond well to PDE5 inhibitors. Off-label use in men is well-established in clinical practice.
Works When Viagra/Cialis Don't
Because PT-141 operates through a completely different mechanism (central nervous system vs. vascular), it can produce results in patients where PDE5 inhibitors have failed. If the issue is desire rather than blood flow, PT-141 addresses the actual problem.
Rapid Onset
Effects typically begin within 30-60 minutes of subcutaneous injection. This is an on-demand medication — you use it when you need it, not every day. Effects can last anywhere from 6 to 72 hours depending on the individual, giving a wide window of activity.
Addresses Both Psychological and Physiological Low Desire
Low libido can stem from hormonal, neurochemical, psychological, or relationship factors. PT-141 works on the neurochemical component — increasing dopamine in desire pathways — which can help even when the underlying cause is multifactorial. It's not a fix for relationship issues, but it directly addresses the brain chemistry of desire.
Important context: PT-141 has full FDA approval based on Phase 3 clinical trials in women with HSDD. The evidence base for men is strong but consists primarily of Phase 2 trials and clinical experience. The mechanism of action (melanocortin receptor activation) is well-characterized and not sex-specific.
HOW PT-141 WORKS
PT-141's mechanism of action is what makes it unique in sexual dysfunction treatment. It doesn't affect blood flow. It works entirely through the central nervous system.
Activates Melanocortin-4 Receptors (MC4R)
PT-141 is a melanocortin receptor agonist. It binds to and activates MC4R receptors concentrated in the hypothalamus — the brain region that regulates sexual behavior, appetite, and autonomic function. This is the primary mechanism behind its pro-sexual effects. MC4R activation is the switch that initiates the desire cascade.
Increases Dopamine in Desire Pathways
MC4R activation triggers increased dopamine release in the brain's mesolimbic reward system — the same pathway involved in motivation, pleasure, and wanting. Dopamine is the neurochemical of desire. By upregulating dopamine signaling in these specific pathways, PT-141 produces genuine increases in sexual motivation, not just physical capability.
Central Nervous System Action (Not Vascular)
This is the critical distinction. PT-141's mechanism is entirely independent of the vascular system. It doesn't dilate blood vessels. It doesn't inhibit PDE5. It works upstream of all that — at the level of desire and motivation in the brain. Downstream physical arousal responses follow from the central activation, but the primary effect is neurological.
Derived from Melanotan II Research
PT-141 is a cyclic heptapeptide (7 amino acids) derived from melanotan II, which was originally developed as a sunless tanning agent. During clinical trials, melanotan II consistently produced spontaneous erections and increased sexual desire in male subjects — a side effect significant enough to warrant development of a dedicated compound. PT-141 was engineered to isolate the sexual effects while minimizing the melanogenic (tanning) activity.
No Hormonal Mechanism
PT-141 does not alter testosterone, estrogen, or any other hormone levels. It doesn't work through the endocrine system. This makes it a useful option for patients who already have adequate hormone levels (including those on TRT) but still experience low desire. It fills a gap that hormone therapy alone can't always address.
PT-141 VS VIAGRA / CIALIS
PT-141 and PDE5 inhibitors are not competitors — they solve different problems through different mechanisms. Understanding the distinction is critical for choosing the right treatment.
| PT-141 (Bremelanotide) | Viagra / Cialis / Tadalafil | |
|---|---|---|
| Target | Brain (desire & arousal) | Blood vessels (erection mechanics) |
| Mechanism | Melanocortin-4 receptor agonist | PDE5 enzyme inhibitor |
| What It Fixes | Low desire, low arousal, low libido | Erectile dysfunction (blood flow) |
| Works for Women | Yes (FDA-approved for HSDD) | No (not indicated) |
| Route | Subcutaneous injection | Oral tablet |
| Frequency | On-demand (max 8x/month) | On-demand or daily (tadalafil) |
| Onset | 30-60 minutes | 30-60 minutes |
| Duration | 6-72 hours | 4-36 hours |
| Cost at Moonshot | $250/mo (compounded) | $70/mo (daily tadalafil) |
When PT-141 Is the Better Choice
When the primary issue is low desire or low libido — you can get an erection but don't want to. When PDE5 inhibitors haven't worked or only partially worked. When you're a woman (PDE5 inhibitors aren't indicated for women). When you're on TRT but still have desire issues.
When PDE5 Inhibitors Are the Better Choice
When the primary issue is achieving or maintaining an erection despite normal desire. When you prefer oral medication over injection. When you want daily dosing for spontaneity (daily tadalafil). When the issue is clearly vascular — blood flow, not motivation.
Many patients use both. PT-141 for desire and a PDE5 inhibitor for mechanics. This combination addresses the full spectrum of sexual function — wanting and performing. Your provider can help determine which approach (or combination) makes sense for your situation. Moonshot Medical offers both PT-141 ($250/mo) and daily tadalafil ($70/mo).
PT-141 DOSING & ADMINISTRATION
PT-141 is an on-demand medication, not a daily therapy. It's administered as a subcutaneous injection before anticipated sexual activity. Here are the standard protocol parameters:
Standard Dose
1.75mg subcutaneous injection. This is the FDA-approved dose. It's administered into the abdomen or thigh using a small insulin-type syringe. Dose adjustments may be made by your provider based on response and tolerability.
Timing
Approximately 45 minutes before anticipated sexual activity. Effects typically begin within 30-60 minutes and can last 6-72 hours depending on the individual. This gives a wide window — it's not something you need to time precisely.
Frequency Limits
Maximum 1 dose per 24-hour period. Maximum 8 doses per month per FDA labeling. This is not a daily medication — it's used as needed. There is no need for daily maintenance dosing, cycling, or loading.
Administration
Subcutaneous injection in the abdomen or upper thigh. Uses a small (29-31 gauge) insulin syringe. The injection is virtually painless. Your provider will train you on proper injection technique at your initial visit.
Storage
Refrigerate after reconstitution. Unreconstituted powder can be stored at room temperature. Once reconstituted, use within 30 days. Keep away from direct light and heat.
Not a Daily Peptide
Unlike TRT, GH peptides, or BPC-157, PT-141 is used strictly on-demand. There's no daily injection schedule, no titration period, and no need to build up levels over time. You use it when you want it, and it works that session.
Note: Dosing should be determined by your provider based on your medical history, current medications, and treatment goals. The 1.75mg dose is the standard FDA-approved dose, but your provider may adjust based on your individual response and tolerability.
PT-141 SIDE EFFECTS & RISKS
PT-141 went through full FDA Phase 3 clinical trials, so the side effect profile is well-characterized. No serious adverse events were reported at therapeutic doses. Here's what to expect:
Nausea (~40%): The most common side effect. Usually mild, peaks approximately 2 hours after injection, and resolves within a few hours. This is the main reason some patients discontinue. Taking the injection with a light meal and staying hydrated can help. Most patients report nausea diminishes with subsequent doses.
Facial flushing: A warm, flushed feeling in the face. This is a common melanocortin receptor response and is harmless. It typically resolves within a few hours and many patients don't find it bothersome.
Headache: Reported by some patients, generally mild and transient. Standard over-the-counter treatment is sufficient if it occurs.
Temporary blood pressure increase: PT-141 can cause a transient rise in blood pressure that typically resolves within 12 hours. This is why it's contraindicated in uncontrolled hypertension. Your provider will check your blood pressure before prescribing.
Injection site reactions: Minor redness or irritation at the injection site. Typically resolves within minutes to hours. Rotating injection sites helps minimize this.
Skin hyperpigmentation (rare): PT-141's melanocortin activity can theoretically cause darkening of skin or gums with repeated use. This is rare at therapeutic doses and the on-demand dosing schedule (max 8x/month), but it's worth mentioning given PT-141's origins in tanning peptide research.
Serious adverse events: None reported at therapeutic doses in Phase 3 clinical trials. The FDA approval process requires extensive safety data — PT-141 passed that bar.
The nausea is real but manageable. About 40% of patients experience some nausea, but it's usually mild and temporary. It tends to decrease with subsequent doses as your body adapts. If nausea is a concern, your provider can discuss strategies to minimize it. The side effect profile overall is mild — this is an FDA-approved medication with a well-established safety record.
WHO IS PT-141 FOR?
PT-141 is a targeted treatment for low sexual desire and arousal. It's most appropriate for patients who have identified desire as the primary issue — not performance, not hormone levels, but wanting.
Good Candidates
Women with HSDD — This is the FDA-approved indication. Women experiencing persistently low sexual desire that causes personal distress. PT-141 is one of very few treatments with demonstrated efficacy for female sexual desire disorders.
Men with low libido — Men experiencing low sexual desire regardless of erectile function. This includes men who can achieve erections but have diminished interest in sex. Off-label use in men is well-supported by clinical data.
PDE5 inhibitor non-responders — Men who don't respond adequately to Viagra, Cialis, or tadalafil. If the underlying issue is desire rather than blood flow, switching mechanisms makes clinical sense.
TRT patients with persistent low libido — A common scenario: testosterone levels are optimized but desire hasn't fully returned. Testosterone addresses some but not all components of sexual desire. PT-141 targets the neurochemical component that TRT may not fully resolve.
Patients seeking on-demand desire enhancement — For people who want situational boost in desire rather than a daily medication. PT-141's on-demand dosing fits this use case well.
Who Should Avoid PT-141
Uncontrolled hypertension — PT-141 can cause transient increases in blood pressure. Patients with uncontrolled high blood pressure should not use PT-141 until blood pressure is managed.
Cardiovascular disease — As a precaution, patients with active cardiovascular conditions should discuss the risk-benefit profile with their provider before starting PT-141.
Pregnant or nursing women — Insufficient safety data in pregnancy and lactation. Standard precaution for any peptide therapy.
Bottom line: PT-141 fills a gap that no other medication addresses — desire at the brain level. If your issue is wanting (not performance), and especially if PDE5 inhibitors haven't solved the problem, PT-141 is worth discussing with your provider.
HOW TO GET PT-141
PT-141 has the strongest regulatory position of any peptide — it has full FDA approval (Vyleesi, 2019). It's available both as brand-name Vyleesi and as a compounded preparation through licensed 503A pharmacies.
FDA-Approved Status
PT-141 (bremelanotide) received full FDA approval in June 2019 under the brand name Vyleesi. This means it has passed the FDA's rigorous review process including Phase 3 clinical trials demonstrating safety and efficacy. This is not a gray-area compound — it's a fully approved prescription medication.
Brand vs. Compounded
Brand-name Vyleesi costs approximately $900+ per month. Compounded PT-141 from a licensed 503A compounding pharmacy contains the same active compound at a fraction of the cost. The active molecule is identical — the difference is packaging, marketing, and price. Moonshot Medical works with a licensed 503A compounding pharmacy to provide pharmaceutical-grade PT-141.
What You Get
A pharmaceutical-grade compound with verified purity and potency. A personalized protocol based on your medical history and goals. Medical oversight including blood pressure monitoring. Injection training at your initial visit. This is a managed therapeutic protocol, not a DIY project.
A prescription is required. PT-141 is a prescription medication — you need a licensed provider to evaluate you, confirm the indication, check for contraindications (particularly blood pressure), and write the prescription. This isn't a regulatory hoop — it's appropriate medical practice for a compound that affects cardiovascular parameters.
PT-141 COST AT MOONSHOT MEDICAL
Transparent pricing. No hidden fees. Here's what PT-141 therapy costs at Moonshot Medical in Park Ridge, IL:
$250/mo
PT-141 (compounded) — pharmaceutical-grade from a licensed 503A compounding pharmacy
Included
Medical oversight, personalized protocol, injection training, blood pressure monitoring
$70/mo
Daily tadalafil also available — many patients use both for comprehensive sexual health
For comparison, brand-name Vyleesi costs approximately $900+ per month. The compounded version uses the same active compound at a fraction of the cost. Insurance does not typically cover either option — peptide therapy is a cash-pay service at all clinics, not just ours.
An initial consultation is required before starting PT-141 therapy. This is where we review your medical history, check blood pressure, discuss contraindications, and determine if PT-141 is appropriate for your situation.
See our full peptide therapy services and pricing page for details on all available peptides.
PT-141 FAQ
What is PT-141?
PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin-4 receptors in the brain to increase sexual desire and arousal. It was FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike Viagra or Cialis, PT-141 works through the central nervous system to address desire at the brain level, not just blood flow mechanics.
Is PT-141 FDA-approved?
Yes. PT-141 (bremelanotide) received full FDA approval in June 2019 under the brand name Vyleesi for HSDD in premenopausal women. It is also available as a compounded preparation through licensed 503A compounding pharmacies at a lower cost. This gives PT-141 the strongest regulatory position of any peptide — full FDA approval based on Phase 3 clinical trial data.
How is PT-141 different from Viagra or Cialis?
They solve different problems through different mechanisms. PT-141 works on the central nervous system to increase desire and arousal at the brain level. Viagra/Cialis work on blood flow to support erection mechanics. PT-141 can work when PDE5 inhibitors don't because the issue is desire, not vascular function. Many patients use both — they're complementary, not competing.
How long does PT-141 take to work?
PT-141 typically takes effect within 30-60 minutes of subcutaneous injection. Effects can last 6-72 hours depending on the individual, giving a wide window of activity. It is used on-demand before anticipated sexual activity — not as a daily medication.
Does PT-141 work for men?
Yes. While the FDA approval is specifically for premenopausal women with HSDD, the melanocortin receptor system is not sex-specific. Clinical studies have demonstrated efficacy in men with erectile dysfunction and low desire. Off-label use in men is well-established in clinical practice. PT-141 is particularly useful for men who don't respond adequately to PDE5 inhibitors or who have desire issues rather than blood flow issues.
How much does PT-141 cost?
At Moonshot Medical in Park Ridge, IL, compounded PT-141 costs $250 per month. This includes the pharmaceutical-grade compound from a licensed 503A compounding pharmacy, medical oversight, injection training, and monitoring. Brand-name Vyleesi costs $900+ per month. Insurance does not typically cover either option.
References
- 1. Kingsberg SA, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder." Obstet Gynecol. 2019;134(5):899-908.
- 2. Clayton AH, et al. "Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial." Womens Health. 2016;12(3):325-337.
- 3. Safarinejad MR. "Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder." J Sex Med. 2008;5(3):798-814.
- 4. Diamond LE, et al. "An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141)." J Sex Med. 2006;3(4):628-638.
- 5. FDA. "Vyleesi (bremelanotide) prescribing information." 2019.
INTERESTED IN PT-141?
Book a consultation to find out if PT-141 is right for you. We'll review your history, check for contraindications, and build a personalized protocol.
Book Consultation